Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ …
M Fehlings, Y Simoni, HL Penny, E Becht… - Nature …, 2018 - nature.com
Nature communications, 2018•nature.com
The original version of this Article omitted a declaration from the competing interests
statement, which should have included the following:'RDS is a cofounder, stock holder, and
scientific advisory board member of Jounce Therapeutics and Neon Therapeutics, and a
member of the scientific advisory boards of BioLegend, Constellation, Lytix, and NGM. He
also received research funding from Janssen and Agios.'. This has now been corrected in
both the PDF and HTML versions of the Article.
statement, which should have included the following:'RDS is a cofounder, stock holder, and
scientific advisory board member of Jounce Therapeutics and Neon Therapeutics, and a
member of the scientific advisory boards of BioLegend, Constellation, Lytix, and NGM. He
also received research funding from Janssen and Agios.'. This has now been corrected in
both the PDF and HTML versions of the Article.
The original version of this Article omitted a declaration from the competing interests statement, which should have included the following:‘RDS is a cofounder, stock holder, and scientific advisory board member of Jounce Therapeutics and Neon Therapeutics, and a member of the scientific advisory boards of BioLegend, Constellation, Lytix, and NGM. He also received research funding from Janssen and Agios.’. This has now been corrected in both the PDF and HTML versions of the Article.
nature.com